Kristine Hickman
Nurse Practitioner · Salisbury, MDNPI 1629515812
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,600, 2.7 times the $596 reported in 2021. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$706
- Otsuka America Pharmaceutical, Inc.$667
- Alkermes, Inc.$519
- Neurocrine Biosciences, Inc.$514
- Lundbeck LLC$439
- Teva Pharmaceuticals USA, Inc.$402
- plus $2K from 14 others
What the payments were for
- Food & beverage$5,099100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $706 |
| Otsuka America Pharmaceutical, Inc. | 26 | $667 |
| Alkermes, Inc. | 24 | $519 |
| Neurocrine Biosciences, Inc. | 25 | $514 |
| Lundbeck LLC | 25 | $439 |
| Teva Pharmaceuticals USA, Inc. | 23 | $402 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $279 |
| E.r. Squibb & Sons, L.L.C. | 15 | $267 |
| Axsome Therapeutics, Inc. | 8 | $250 |
| Idorsia Pharmaceuticals US Inc | 4 | $232 |
| Vanda Pharmaceuticals Inc. | 5 | $227 |
| Johnson & Johnson | 10 | $201 |
| Indivior Inc. | 9 | $155 |
| Sunovion Pharmaceuticals Inc. | 6 | $112 |
| Gilead | 2 | $46 |
| Tempus AI, Inc | 1 | $27 |
| Exact Sciences | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Abbott | 1 | $18 |
| Tris Pharma Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,123 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 18 | $270,073 |
| Abilify MaintenaAripiprazole | 77 | $206,878 |
| Invega SustennaPaliperidone Palmitate | 61 | $168,148 |
| IngrezzaValbenazine Tosylate | 20 | $152,522 |
| RexultiBrexpiprazole | 95 | $145,880 |
| Invega TrinzaPaliperidone Palmitate | 16 | $127,004 |
| Austedo XrDeutetrabenazine | 20 | $122,467 |
| VraylarCariprazine Hcl | 65 | $91,644 |
| AristadaAripiprazole Lauroxil | 23 | $83,911 |
| UzedyRisperidone | 21 | $75,292 |
| CaplytaLumateperone Tosylate | 15 | $27,148 |
| AuvelityDextromethorphan Hbr/Bupropion | 35 | $26,952 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $22,850 |
| Lurasidone Hcl | 81 | $16,727 |
| Chlorpromazine Hcl | 14 | $14,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $402 | $467,83359 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $667 | $352,759172 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $201 | $295,15177 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $514 | $152,52220 claims |
| Alkermes, Inc.Aristada, Lybalvi | $519 | $106,76137 claims |
| AbbVieVraylar, Fetzima | $706 | $104,17891 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $279 | $27,14815 claims |
| Axsome Therapeutics, Inc.Auvelity | $250 | $26,95235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Other nurse practitioner in Salisbury
- Tanya CliffordSalisbury$10K
- Morgan GaleRockville$292K
- Sherilyn BrinkleyBaltimore$100K
- Michelle TurnerBaltimore$94K
- Nelli ZafmanLutherville$67K
- Ellen LancasterFallston$52K
- Doris TateEaston$34K
- Zeev NemirovskyBaltimore$19K
- Martha ReilleyAnnapolis$18K
- Stephanie ZwonitzerAnnapolis$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.